Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.

Journal of cellular physiology - 1 Sept 2021

Ma Dan, Liu Ping, Wang Ping, Zhou Zhen, Fang Qin, Wang Jishi

Abstract excerpt

Bcr-Abl independent resistance to tyrosine kinase inhibitor (TKI) is a crucial factor lead to relapse or acute leukemia transformation in chronic myeloid leukemia (CML). However, its mechanism is still unclear. Herein, we found that of nine common protein kinases C (PKCs), PKC-β overexpression was significantly related with TKI resistance. Blockage of its expression in CD34+ cells and CML cell lines increased...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arachidonate 5-Lipoxygenase
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to MAP Kinase Signaling System

Share to Protein Kinase C beta

Share to PTEN Phosphohydrolase

Source

Identifiers

PMID: 33561320
DOI: 10.1002/jcp.30301

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.PMID 33561320Read ↗

CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5 ‐ BLTR Signaling PathwaySemantic proximity Read ↗

Dysregulated MAPK signaling pathway in acute myeloid leukemia with RUNX1 mutations.Semantic proximity Read ↗

The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemiaSemantic proximity Read ↗

Network pharmacology-based investigation and experimental validation of the mechanism of Metformin in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Differentially expressed genes responsible for insensitivity of CD34+ cells to kinase inhibitors in patients with chronic myeloid leukemiaSemantic proximity Read ↗

Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug EffluxSemantic proximity Read ↗

Targeting Integrated Stress Response by ISRIB combined with imatinib attenuates STAT5 signaling and eradicates therapy-resistant Chronic Myeloid Leukemia cellsSemantic proximity Read ↗

A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia.Semantic proximity Read ↗

Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemiaSemantic proximity Read ↗

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitorsSemantic proximity Read ↗

Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.Semantic proximity Read ↗

The ALOX5 inhibitor zileuton promotes sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolismSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.